Rate My Professor Jarad Martin

Jarad Martin is Conjoint Professor in the School of Medicine and Public Health at the University of Newcastle's College of Health, Medicine and Wellbeing. A practicing radiation oncologist at Calvary Mater Newcastle, where he serves as Director of Research in the Department of Radiation Oncology, and at GenesisCare Lake Macquarie Private Hospital, he specializes in radiation oncology with a focus on genitourinary (prostate, bladder) and gastrointestinal (oesophagus, pancreas, liver, bowel) cancers. His qualifications include MB ChB from New Zealand, BSc, PhD and DMed(Research) from the University of Queensland, FRANZCR, and GAustMS. Martin's career trajectory includes graduation as a medical practitioner in New Zealand, specialist training in England and at Peter MacCallum Cancer Centre in Melbourne from 2001 to 2005, an advanced fellowship in radiation oncology at Princess Margaret Hospital, University of Toronto, Canada from 2005 to 2006, locum consultant at Royal Brisbane and Women's Hospital in 2006-2007, and Radiation Oncologist at Radiation Oncology Queensland, Toowoomba from 2007 to 2012. Since May 2012, he has been at Calvary Mater Newcastle, and since November 2014 at GenesisCare.

Professor Martin's research integrates clinical practice with advanced studies in hypofractionated radiotherapy, stereotactic body radiotherapy for oligometastases, quality assurance protocols, urethral sparing techniques, and imaging-guided treatments for prostate, bladder, rectal, and oesophageal cancers. He collaborates with multidisciplinary teams and groups like TROG Cancer Research and Laureate Professor Rob Sanson-Fisher’s team to translate research into practice. With over 85 peer-reviewed publications, notable works include senior authorship on the Australasian guidelines for prostate cancer radiotherapy; "DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)" (2022, Journal of Clinical Oncology); "Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial" (2025); and leadership in trials such as TROG 15.01 SPARK, TROG 18.01 NINJA, and PROFIT. His contributions have earned awards including the Canadian Young Oncology Investigator of the Year (2006), Ray Bush Prize (2006), ASCO Merit Award (2006), TROG Orchid Prize (2007), and Chris Atkinson Award for Best Scientific Paper (2012). Through these efforts, Martin advances radiotherapy precision and patient outcomes in oncology.